Navigation Links
Benjamin Custodio Joins Millennium Biotechnologies to Expand International Sales

BASKING RIDGE, N.J., Oct. 28 /PRNewswire-FirstCall/ -- Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: MBTG) today announced that Benjamin Custodio has joined the Company as Executive Vice President of International Sales and a member of the Board of Directors. Mr. Custodio has over 30 years of experience in the pharmaceutical and nutritional supplement industries, specializing in launching new products into international markets.

As Executive Vice President of International Sales, Custodio will leverage his skill set and utilize his strong global relationships to expand the Company's product line globally. Currently, he is the President and CEO of the LCI Group Ltd, a business development group which works with companies around the world in commercializing nutritional supplements, OTC and prescription products. Recently, the LCI Group was successful in coordinating the $360 million sale of the largest custom manufacturer of nutritional supplements in North America. Prior to heading the LCI group, Mr. Custodio was a consultant and member of the Board of Directors of Nu-Life Nutrition Ltd., one of Canada's oldest supplement and nutraceutical companies and once a wholly-owned subsidiary of Vitaquest International Inc., the world's leading custom manufacturer of nutritional and lifestyle products. Over his 30 plus years of industry experience, Mr. Custodio, has acted as the Head of Beverage Unit for Del Monte, President of Wampole Brands, the oldest nutraceutical company in Canada, was an executive with Ciba Geigy/Novartis, and handled international assignments with Johnson & Johnson International.

"Benjamin brings a wealth of experience and contacts to Millennium Biotechnologies," stated Mark Mirken, Chief Executive Officer of Millennium Biotechnologies. "His strong and well respected relationships in Asia will be the source of our international growth. With Benjamin at the helm of international expansion, we expect to achieve an immediate increase in our overseas sales at enhanced profit margins."

According to newly elected board member, Benjamin Custodio, "Millennium Biotechnologies is emerging as a leader in the development of targeted nutritional products in the Clinical, Long Term Care, and Sports markets. With the recent launch of the Company's ready-to-drink products, Resurgex Essential and Resurgex Essential Plus, now is the time for aggressive international expansion. I look forward to working with the Company in leveraging my international contacts for the benefit of its shareholders and believe that numerous overseas expansion opportunities exist in the very near term."

About Millennium

Millennium Biotechnologies is a leader in the development, of targeted nutritional products in the Clinical Nutrition Market and Sports Nutrition Market. Millennium's six marketed products form an advanced line of nutritional formulas. Resurgex Select(R) is a whole foods-based, calorically dense, high-protein nutritional formula developed for cancer patients undergoing chemotherapy or radiation treatments. Resurgex(R) and Resurgex Plus(R) are specialized, anabolic nutritional supplements rich in antioxidants that provide nutritional support post-treatment. Millennium also created Surgex(TM) sports nutrition formula to address the nutritional concerns of professional, Olympic, and amateur elite athletes. These athletes often experience similar symptoms post-workout to those battling immuno-compromised conditions, such as fatigue, loss of lean muscle, oxidative stress, and reduced immune function. Resurgex Essential(TM) and Resurgex Essential Plus(TM) are comprehensive, calorically dense formulas that meet and succeed the nutritional requirements of the assisted living community.

Statements in this news release regarding future financial and operating results, future growth in R&D programs, potential applications of the Millennium's technology, opportunities for the Millennium, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words 'will,' 'believes,' 'plans,' 'anticipates,' 'expects,' 'estimates,' and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward- looking statements including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of Millennium's intellectual property, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in Millennium's periodic reports, including Forms 10-KSB, 10-QSB, 8-K, and other forms filed with the Securities and Exchange Commission ('SEC'). Millennium Biotechnologies, Inc.

SOURCE Millennium Biotechnologies Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Jerome Wilson Joins PRA Internationals Late Phase Service Group
2. Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman
3. Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
4. Karen Walton-Bowen Joins Abt Bio-Pharma Solutions, Inc., as Senior Director, Biometrics
5. Food and Beverage Giant Joins Kannapolis Research Center
6. Mark Sutherland Joins GenVault as Senior Vice President, Business Development
7. Chief Technology Officer Joins ACAMP
8. Charles C. Harwood, Jr., Joins Cellectar, Inc.s Board of Directors
9. Industry Pioneer Joins Profectus BioSciences to Support Innovation in Therapeutic and Preventative Vaccines
10. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
11. Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
Post Your Comments:
(Date:11/24/2015)... , November 24, 2015 SHPG ) announced ... in the Piper Jaffray 27 th Annual Healthcare Conference in ... 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). --> ... Financial Officer, will participate in the Piper Jaffray 27 th ... NY on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... that the remaining 11,000 post-share consolidation (or 1,100,000 ... (the "Series B Warrants") subject to the previously ... November 23, 2015, which will result in the ... effect to the issuance of such shares, there ...
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading ... culture models, has promoted Melanie Aregger to serve as Chief Operating Officer. ... on the management team and was promoted to Head of InSphero Diagnostics ...
(Date:11/24/2015)... 24, 2015 Capricor Therapeutics, Inc. ... the discovery, development and commercialization of first-in-class therapeutics, today ... Officer, is scheduled to present at the 2015 Piper ... a.m. EST, at The Lotte New York Palace Hotel ... . --> . ...
Breaking Biology Technology:
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing need ... analytical tools has been paving the way for ... determination of discrete analytes in clinical, agricultural, environmental, ... being predominantly used in medical applications, however, their ... sectors due to continuous emphasis on improving product ...
(Date:11/10/2015)... 10, 2015 About signature ... helps to identify and verify the identity of ... as the secure and accurate method of authentication ... particular individual because each individual,s signature is highly ... when dynamic signature of an individual is compared ...
Breaking Biology News(10 mins):